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MaOBJECTIVES This study sought to investigate the efﬁcacy of 11C-Pittsburgh B (PiB) positron emission tomography
(PET)/computed tomography (CT) in the diagnosis of cardiac amyloidosis.
BACKGROUND The PiB compound has been promising for detection of amyloid deposits in the brain.
METHODS A total of 22 consecutive patients were enrolled in this prospective pilot study of monoclonal gammopathy
patients with suspected cardiac amyloidosis. The study consisted of a series of 11C-PiB PET/CT, echocardiography, cardiac
magnetic resonance, and endomyocardial biopsy within a 1-month period. In addition, 10 normal subjects were recruited
to determine the most optimal cut-off value for a positive 11C-PiB PET/CT scan.
RESULTS Among the 22 patients, 15 patients were diagnosed as cardiac amyloidosis by endomyocardial biopsy and
5 patients had undergone chemotherapy previously before the 11C-PiB PET/CT. There were no differences in echo-
cardiographic parameters between patients with versus without cardiac amyloidosis, except for a marginal difference
in the left ventricular end-diastolic dimension (median 41.0 mm [range 33.0 to 49.0 mm] vs. 50.0 mm [range 38.0
to 55.0 mm], p ¼ 0.066). 11C-PiB PET/CT was positive in 13 of 15 biopsy-proven cardiac amyloidosis patients,
whereas none of the patients without cardiac amyloidosis demonstrated positive 11C-PiB PET/CT scan results. The
maximal myocardium-to-blood cavity ratio was signiﬁcantly different between patients with versus without cardiac
amyloidosis (median 3.9 [range 1.7 to 19.9] vs. 1.0 [range 0.8 to 1.2], p < 0.001). In association with the signiﬁcant
difference of 11C-PiB uptake in the myocardium between the chemotherapy naïve versus the previous chemotherapy
group (median 10.4 [range 1.7 to 19.9] vs. 2.3 [range 1.7 to 3.8], p ¼ 0.014), all except 1 patient among the
5 previously treated patients had responded to chemotherapy by serum free light chain assay results at the time
of 11C-PiB PET/CT scan.
CONCLUSIONS 11C-PiB PET/CT may be valuable for the diagnosis of cardiac amyloidosis noninvasively. Whether
11C-PiB PET/CT may be a good surrogate marker of active light chain deposition in the myocardium warrants further
investigation in a larger number of patients. (J Am Coll Cardiol Img 2015;8:50–9) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
CT = computed tomography
LGE = late gadolinium
enhancement
LV = left ventricle/ventricular
PET = positron emission
tomography
PiB = Pittsburgh B
RV = right ventricle/ventricular
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51Although the gold standard for the diagnosis of
cardiac amyloidosis is tissue conﬁrmation by endo-
myocardial biopsy (5), this technique is invasive and
may be avoided if the presence of amyloid deposit is
conﬁrmed by histology in another organ and cardiac
amyloidosis can be diagnosed on the basis of nonin-
vasive ﬁndings suggestive of cardiac involvement. In
addition, biopsy of a focal myocardium may not pro-
vide information about the amyloidogenic protein
burden in the whole myocardium, nor does it give
information on whether the protein accumulation is
active.SEE PAGE 60 SUV = standard uptake valueTherefore, there is a clinical need for accurate
assessment of cardiac amyloidosis noninvasively.
Moreover, a method that can give a quantitative es-
timate of amyloid deposit may also provide us with
clinically important information regarding the prog-
nosis. The Pittsburgh B (PiB) compound, a derivative
of thioﬂavin-T, has been used with very good results
for imaging b-amyloid in Alzheimer’s disease (6) and
is believed to bind to amyloid ﬁbril of any type (7).
We expected positron emission tomography (PET)
imaging using this compound to be a promising
choice for imaging cardiac amyloidosis, the pre-
liminary results of which has been successful in a
small case series (8). In this pilot study, we present
the analysis results of a prospective cohort of cardiac
amyloidosis patients examined using the 11C-PiB PET/
computed tomography (CT) scan, together with car-
diac magnetic resonance (CMR), echocardiography,
and endomyocardial biopsy.
METHODS
A detailed version of the Methods section is described
in the Online Appendix.
PATIENT POPULATION. A total of 27 patients were
consecutively assessed for eligibility to this prospec-
tive study from January 2012 to October 2013, which
consisted of a series of 11C-PiB PET/CT, CMR, echo-
cardiography, endomyocardial biopsy, and laboratory
tests such as free light chain assay for monoclonal
gammopathy. The patients were enrolled in this
study if they had serum monoclonal gammopathy
plus any of the following criteria (5):
1. Average left ventricular (LV) thickness $11 mm on
echocardiography in the absence of uncontrolled
hypertension;
2. Unexplained low voltage <0.5 mV in the limb leads
of the 12-lead electrocardiogram; or
3. Biopsy-proven amyloidosis in any other organ.Among the 27 patients, 2 patients refused
endomyocardial biopsy, 2 patients refused to
take 11C-PiB PET/CT despite endomyocardial
biopsy, and 1 patient refused both 11C-PiB
PET/CT and endomyocardial biopsy. There-
fore, the ﬁnal target population for this
analysis was 22 patients. This study was
conducted according to the principles out-
lined in the Declaration of Helsinki. All pa-
tients gave written informed consent to this
prospective study, the protocol of which was
approved by the Institutional Review Board
of Seoul National University Hospital. The
11C-PiB PET/CT, CMR, echocardiography, and
endomyocardial biopsy were completed within 1
month of enrollment. All except 1 patient, who had a
history of coronary revascularization for a single-
vessel disease, were void of any history of signiﬁ-
cant coronary artery disease. In addition, all patients
denied any history of myocardial infarction, which
was also conﬁrmed by the late gadolinium enhance-
ment (LGE) pattern in CMR. The patients were divided
into a cardiac amyloidosis group versus no cardiac
amyloidosis group, according to the endomyocardial
biopsy results, and the cardiac amyloidosis group
was divided further into a chemotherapy naïve group
versus the previous chemotherapy group according
to whether the patient had undergone previous
chemotherapy before the 11C-PiB PET/CT scan.
In addition,we enrolled 10normal subjects (4males,
age range 37 to 80 years) without any evidence of heart
disease to determine the cut-off value of the positive
11C-PiB PET/CT scan.
11C-PIB PET/CT SCAN AND ANALYSIS OF PET
RESULTS. After low-dose CT scanning, 555 MBq of
11C-PiB was injected through the antecubital vein,
followed by an emission scan 30 min after the tracer
injection using a PET/CT scanner with a spatial
resolution of 4.2 mm (Biograph 40, Siemens Medical
Solutions, Knoxville, Tennessee). Imaging was per-
formed in 3-dimensional mode for 3 min per bed po-
sition after 30 min of tracer injection. All appropriate
corrections for scanner normalization, dead time,
decay, scatter, randoms, and attenuation were
applied. Images were reconstructed on 256  256
matrices using an ordered-subset expectation maxi-
mization method (4 iterations, 8 subsets) with the
application of a 5-mm Gaussian ﬁlter. Images were
displayed on transaxial, coronal, and sagittal planes
of 5-mm slice thickness.
The standard uptake value (SUV) of the myocar-
dium was measured by drawing the contour of the
whole LV at an approximate thickness of 10 mm
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52from the base to apex. The maximal SUV was deﬁned
as the maximal SUV in all of the volume of interest
(VOIs) analyzed. The mean SUV was deﬁned as
the mean SUV of the total voxels in the VOI. The
maximal/mean myocardium to blood cavity ratio was
deﬁned as the maximal/mean SUV of the myocardial
VOI divided by the mean SUV of the descending
thoracic aorta VOI. The mean SUV of the right
ventricle (RV) was analyzed in a similar manner
from the RV free wall.
To determine the optimal cut-off value of 11C-PiB
PET/CT, we analyzed the images of 10 sex-matched
normal subjects (Table 1). As the amyloid protein
deposit may be heterogeneous (9), the cut-off value
was determined with the maximal rather than the
mean LV myocardium to blood cavity ratio. The
maximal LV myocardium to blood cavity ratio did
not exceed 1.6 in all control subjects. In addition, 2
weeks later, intraobserver variability of the maximal
LV myocardium to blood cavity ratio in these pa-
tients did not exceed 0.2 in all subjects. Therefore,
the cut-off maximal LV myocardium to blood cavity
ratio of 2.0 was determined on this basis (maximal
value of the maximal LV myocardium to blood
cavity ratio in all individuals þ [2  intraobserver
variability]).
All 11C-PiB PET/CT images were quantiﬁed by a
single experienced investigator blinded to all other
ﬁndings of the patient. Additionally, the left myo-
cardial wall was divided into 16 standardized seg-
ments according to the deﬁnition of the American
Heart Association (10).TABLE 1 11C-PiB PET/CT Results of Normal Control Subjects
Patient # Age, yrs Sex
PiB PET/CT
Maximal LV
Myocardium-Blood
Cavity Ratio
Mean LV
Myocardium-Blood
Cavity Ratio
1 80 M 1.40 1.17
2 59 M 1.60 1.11
3 65 F 1.31 1.11
4 54 F 1.22 1.01
5 56 F 1.39 0.88
6 51 F 1.17 1.10
7 59 F 1.00 0.94
8 58 F 1.27 1.10
9 37 M 0.88 0.76
10 55 M 1.49 1.26
The maximal SUV was deﬁned as the maximal SUV in all of the VOIs analyzed.
The mean SUV was deﬁned as the mean SUV of the total voxels in the VOIs. The
maximal/mean myocardium to blood cavity ratio was deﬁned as the maximal/mean
SUV of the myocardial VOIs divided by the mean SUV of the descending thoracic
aorta VOIs.
CT ¼ computed tomography; LV ¼ left ventricular; PET ¼ positron emission
tomography; PiB ¼ Pittsburgh B; SUV ¼ standard uptake value; VOI ¼ volume of
interest.CARDIAC MAGNETIC RESONANCE. The electrocardio-
gram-gated CMR images were taken using a stan-
dard 1.5-T scanner (Sonata Magnetom, Siemens
Healthcare, Erlangen, Germany) or 3.0-T scanner
(Trio, Siemens Healthcare) equipped with 6-channel
phased-array receiver coils under the standard pro-
tocols. After taking initial scout images, steady-state
free precession cine images were acquired under an
adequate breath-hold for cine images. The imaging
parameters for the cine images were: echo time 1.6
ms, repetition time 3.6 ms, ﬂip angle 80, matrix
size 256  150, slice thickness 6 mm with 4 mm gap
between adjacent slices, FOV 240  300 cm, and
temporal resolution 32 ms. The LGE images were
obtained after 10 min of intravenous gadolinium in-
jection (0.1 mmol/kg Magnevist, Schering, Berlin,
Germany) with 8 mm thickness, 2 mm interval. The
imaging parameters for the LGE images were: slice
thickness 8 mm, interslice gap 2 mm, echo time
42 ms, repetition time 9.1 ms, ﬂip angle 13, and in-
plane resolution 1.4  1.9 mm. Inversion delay time
varied according to the time to null the normal
myocardium, especially because it is often difﬁcult to
determine the optimal inversion time in cardiac
amyloidosis. All CMR images were analyzed by a
single experienced investigator blinded to other
ﬁndings of the patient.
STATISTICAL ANALYSIS. Continuous variables were
presented as median (range) and number (percent)
for categorical variables. The Mann-Whitney U test
was used to compare continuous variables. The
Fisher exact test was used to compare the differences
in categorical data between the groups. The degree of
correlation between the parameters was expressed
with Spearman’s r. A 2-tailed p < 0.05 was considered
statistically signiﬁcant.
RESULTS
A total of 22 patients were enrolled in this prospective
pilot study, among whom 15 patients were diagnosed
with cardiac amyloidosis using tissue conﬁrmation by
endomyocardial biopsy. Baseline clinical character-
istics of these patients are summarized in Table 2. In
the biopsy-proven cardiac amyloidosis group, the
median age of the patients was 64 years, and 7 pa-
tients were male. Patients #1 to #15 were diagnosed
with cardiac amyloidosis by positive Congo red
staining and amyloid P staining on endomyocardial
biopsy. The immunostaining of the endomyocardial
biopsy samples were also matched with the serum
free light chain assay results. All patients had AL
amyloidosis, and there were no patients diagnosed
with senile amyloidosis.
TABLE 2 Baseline Clinical Data and 11C-PiB PET/CT Results of Each Study Participant
Patient # Age, yrs Sex
Biopsy PiB PET/CT
ECG Low
Voltage
Chemotherapy
Before the
Enrollment
Amyloid In
Other Organs
DFLC (Before
Chemotherapy)
DFLC (After
Chemotherapy)
Immunohisto-
chemistry Uptake
Maximal LV
Myocardium-Blood
Cavity Ratio
Mean LV
Myocardium-Blood
Cavity Ratio
1 59 F l Yes 3.86 2.27 Yes No
2 51 F l Yes 13.94 4.94 Yes No
3 64 M l Yes 19.92 8.92 Yes No
4 75 F l Yes 18.03 10.70 Yes No Kidney
5 60 F k Yes 13.51 7.60 Yes No Kidney
6 79 F k Yes 3.63 1.69 Yes No
7 64 M l Yes 4.26 2.28 Yes No
8 67 M l Yes 15.89 9.41 Yes No
9 72 M k Yes 7.27 3.73 Yes No
10 61 M l Yes 2.29 0.99 No MD#3/Auto-PBSCT 117 (27/144) 26 (17/43)
11 53 M l Yes 3.81 1.08 Yes MD#1 207 (28/235) 38 (3/41)
12 69 F l Yes 2.39 1.17 No MD#1 144 (16/160) 70 (32/102)
13 51 F k Yes 2.05 1.19 Yes TD#1 350 (606/256) 48 (50/2)
14 45 F k No 1.69 0.95 Yes No Kidney
15 62 M l No 1.68 0.64 Yes TD #6 35/1,151 (1,116)
16 79 M Nonamyloid No 0.92 0.87 Yes No
17 67 M Nonamyloid No 1.03 1.00 No No
18 76 F Nonamyloid No 0.97 0.96 No No
19 50 F Nonamyloid No 1.23 0.95 Yes No Kidney, liver
20 77 F Nonamyloid No 0.89 0.76 No No
21 76 F Nonamyloid No 0.76 0.66 Yes No
22 73 M Nonamyloid No 1.11 0.98 Yes No
Individual clinical and 11C-PiB PET/CT results of the study participants are listed. All patients were diagnosed with cardiac amyloidosis by positive Congo red and amyloid P immunohistochemical staining on
endomyocardial biopsy. The immunostaining of the endomyocardial biopsy samples were also matched with the serum free light chain assay results. A cutoff value for positive versus negative 11C-PiB PET/CT
was deﬁned as maximal myocardium-to-blood cavity ratio$2.0 on the basis of results of control subjects in Table 1. The difference between the involved and uninvolved free light chain levels is shown in the
DFLC column with k and l levels in the parenthesis, respectively. #n indicates number of cycles of chemotherapy.
ECG ¼ electrocardiogram; FLC ¼ free light chain; MD ¼ melphalan þ dexamethasone; PBSCT ¼ peripheral blood stem cell transplantation; TD ¼ thalidomide þ dexamethasone; other abbreviations as in
Table 1.
TABLE 3 Echocardiography Data From All Study Participants
Biopsy-Proven Cardiac Amyloidosis
p ValueYes (n ¼ 15) No (n ¼ 7)
LV end-diastolic
dimension, mm
41.0 (33.0–49.0) 47.0 (38.0–55.0) 0.066
LV ejection
fraction, %
56.0 (34.0–76.0) 64.5 (29.0–75.0) 0.731
Average wall
thickness, mm
12.0 (9.0–17.0) 11.0 (9.5–16.0) 0.731
E velocity, m/s 0.80 (0.40–1.3) 0.65 (0.40–0.97) 0.368
e0 velocity at septal
annulus, cm/s
4.3 (1.7–6.2) 3.6 (2.8–5.1) 0.569
LV hypertrophy 53.3 (8.0) 42.9 (3.0) >0.999
Diastolic dysfunction
grade
0.211
I 33.3 (5.0) 57.1 (4.0)
II 33.3 (5.0) 42.9 (3.0)
III 33.3 (5.0) 0.0 (0.0)
Values are median (range) or % (n). The echocardiography was done at the time
of enrollment. The e0 velocity was measured at the septal side of the mitral
annulus.
LV ¼ left ventricular.
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53A detailed description on the amyloidosis status of
the enrolled patients is summarized in Table 2. There
were 3 patients with concomitant renal amyloidosis
in the biopsy-proven cardiac amyloidosis group in
comparison with 1 patient having renal and hepatic
amyloidosis in the no cardiac amyloidosis group. In
addition, 5 patients (Patients #10 to #13, and #15) had
undergone previous chemotherapy before the diag-
nosis of cardiac amyloidosis by endomyocardial
biopsy. The serum free light chain assay results
before and after the chemotherapy were available in
4 patients (Patients #10 to #13), all of whom showed
a partial response of $50% decrease in the difference
between involved and uninvolved free light chain
levels (11). The initial serum free light chain assay
result was unavailable in patient 15 because the
patient was transferred from another hospital. No
patients in the no cardiac amyloidosis group had
undergone previous chemotherapy for monoclonal
gammopathy.
The echocardiography data for all study partici-
pants are summarized in Table 3. There were no
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54differences in the echocardiographic parameters be-
tween the biopsy-proven cardiac amyloidosis group
(Patients #1 to #15) and the no cardiac amyloidosis
group (Patients #16 to #22), except for a marginal
difference in the LV end-diastolic diameter (median
41.0 mm [range 33.0 to 49.0 mm] vs. 50.0 mm [range
38.0 to 55.0 mm], p ¼ 0.066 with Mann-Whitney U
test). Although grade III diastolic dysfunction was
demonstrable only in patients in the biopsy-proven
cardiac amyloidosis group, the overall degree of dia-
stolic dysfunction was not signiﬁcantly different be-
tween the 2 groups (p ¼ 0.211).M
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FIGURE 1 Comparison of the Standard Uptake Value Ratio of 11C-PiB
(A and B) The patients were grouped into those with endomyocardial b
maximal (A) and the mean (B) 11C-Pittsburgh B (PiB) left ventricular (LV)
compared between the cardiac amyloidosis versus no cardiac amyloidos
myocardium to blood cavity ratio in between patients with cardiac amyl
maximal LV myocardium to blood cavity SUV ratio and a p value of 0.003
Whitney U test. (C and D) The biopsy-proven cardiac amyloidosis patients
had undergone previous chemotherapy. The maximal (C) and the mean (
between the chemotherapy naïve and the previous chemotherapy patien
cavity SUV ratio and a p value of 0.010 for mean LV myocardium to blood
and C denotes the cut-off value for a positive 11C-PiB positron emission to
the median value of each group. (E) The correlation between mean righ
myocardium to blood cavity ratio. Spearman’s r ¼ 0.912, p < 0.001.Using the maximal LV myocardium to blood cavity
SUV ratio of 2.0 for the cut-off of a positive 11C-PiB
PET/CT scan derived from 10 normal subjects,
there was no patient with a false-positive 11C-PiB
PET/CT scan result in the no cardiac amyloidosis
group. In contrast, there was 1 patient each in the
chemotherapy-naïve (Patient #14) and the previous
chemotherapy group (Patient #15) with false-negative
11C-PiB PET/CT results (maximal LV myocardium to
blood cavity ratio 1.69 and 1.68, respectively).
The maximal and the mean LV myocardium to
blood cavity SUV ratios were signiﬁcantly differentM
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in the Study Participants
iopsy-proven cardiac amyloidosis versus no cardiac amyloidosis. The
myocardium to blood cavity standard uptake value (SUV) ratios were
is groups. Note that there was no overlap of the maximal LV
oidosis versus with no cardiac amyloidosis. A p value <0.001 for
for mean LV myocardium to blood cavity SUV ratio, both with Mann-
were grouped into chemotherapy naïve patients and the patients who
D) 11C-PiB LV myocardium to blood cavity SUV ratios were compared
ts. There was a p value of 0.014 for maximal LV myocardium to blood
cavity SUV ratio, both with Mann-Whitney U test. The dotted line in A
mography/computed tomography. Horizontal lines in A to D indicate
t ventricular (RV) myocardium to blood cavity ratio versus mean LV
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55between the cardiac amyloidosis group and the no
cardiac amyloidosis group (median 3.86 [range 1.68 to
19.92] vs. 0.97 [range 0.76 to 1.23], p < 0.001 for
maximal LV myocardium to blood cavity ratio
[Figure 1A]; median 2.27 [range 0.64 to 10.70] vs. 0.95
[range 0.66 to 1.00], p ¼ 0.003 for mean LV myocar-
dium to blood cavity ratio [Figure 1B]). The maximal
and the mean LV myocardium to blood cavity ratios
were also signiﬁcantly different between the chemo-
therapy naïve group and the previous chemotherapy
group (median 10.39 [range 1.69 to 19.92] vs. 2.29
[range 1.68 to 3.81], p ¼ 0.014 for maximal LV
myocardium to blood cavity ratio [Figure 1C]; median
4.34 [range 0.95 to 10.70] vs. 1.08 [range 0.64 to 1.19],
p ¼ 0.010 for mean LV myocardium to blood cavity
ratio [Figure 1D]). It was also notable that the degree
of mean RV uptake was proportionate to the degree of
mean LV uptake (Spearman’s r ¼ 0.912, p < 0.001
between mean LV vs. mean RV myocardium to blood
cavity ratio) (Figure 1E).
Figure 2 shows the representative 11C-PiB PET/CT
scan and the corresponding LGE-CMR images of
chemotherapy-naïve cardiac amyloidosis patientsFIGURE 2 Representative 11C-PiB PET/CT Images of the Study Partic
(A) Diffuse, homogeneous uptake pattern in patient 9. The uptake of 11
enhancement pattern was noted at the late gadolinium enhancement (L
uptake pattern in patient 5. Although there was uptake noted at other
inferoseptum and, to a lesser degree, at the lateral segment. Heterogen
image. (C) A representative 11C-PiB positron emission tomography (PET)
chemotherapy before 11C-PiB PET/CT (Patient #12). The 11C-PiB uptake w
ring enhancement pattern. (D) A representative negative 11C-PiB PET/CT
(Patient #18). The LGE-CMR image was also normal. Abbreviations as in(Figures 2A and 2B), a cardiac amyloidosis patient who
had undergone previous chemotherapy before 11C-PiB
PET/CT scan (Figure 2C), and a patient from the no
cardiac amyloidosis group (Figure 2D). The 11C-PiB
uptake pattern was mainly diffuse and homogeneous
at the LV as well as the RV (Figure 2A, patient 9).
However, in some cases, the hot uptake was more
striking at localized areas such as the septal and
lateral segments (Figure 2B, patient 5). Although the
maximal LV myocardium to blood cavity ratio was
numerically higher in the cardiac amyloidosis pa-
tients who had undergone previous chemotherapy,
the 11C-PiB uptake was only marginally stronger in the
cardiac amyloidosis patients who had undergone
previous chemotherapy (Figure 2C) compared with
the patients without cardiac amyloidosis (Figure 2D)
on visual inspection.
The gadolinium-enhanced CMR was not performed
in 3 patients in the 11C-PiB PET/CT-negative group
because of signiﬁcant azotemia (creatinine clearance
#30 ml/kg/min). Diverse patterns of LGE were noted
in the patients, ranging from no LGE, to a more
typical subendocardial ring enhancement, and to aipants
C-PiB was noted at both the LV and RV. Subendocardial ring
GE)-cardiac magnetic resonance (CMR) image. (B) Heterogeneous
regions, the uptake of 11C-PiB was more strongly positive at the
eous transmural enhancement pattern was present at the LGE-CMR
/computed tomography (CT) image of a patient who had undergone
as marginally elevated, and LGE-CMR demonstrated a subendocardial
scan image of a patient who did not have cardiac amyloidosis
Figure 1.
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56heterogeneous transmural LGE pattern (Table 4).
Although only subendocardial ring enhancement
pattern was noted in the previous chemotherapy
group (Figure 2C), heterogeneous transmural LGE
pattern was also seen (Figure 2B), as well as the sub-
endocardial ring enhancement pattern in the
chemotherapy naïve group (Figure 2A). There was 1
false-positive CMR case (Patient #16) in the biopsy-
negative group. There was 1 false-negative CMR case
(Patient #2) in the biopsy-positive group, which was
correctly diagnosed with 11C-PiB PET/CT (Figure 3),
and 1 patient had both false-negative CMR and 11C-PiB
PET/CT (Patient #15) (Table 5).
Overall, the sensitivity and speciﬁcity of 11C-PiB
PET/CT for the diagnosis of cardiac amyloidosis was
0.87 (95% conﬁdence interval [CI]: 0.58 to 0.98) and
1.00 (95% CI: 0.56 to 1.00), whereas for CMR it was
0.83 (95% CI: 0.51 to 0.97) and 0.85 (95% CI: 0.42 to
0.99). The diagnostic accuracy of 11C-PiB PET/CT was
0.91, whereas for CMR it was 0.84.
DISCUSSION
Although the gold standard diagnostic tool for
cardiac amyloidosis is endomyocardial biopsy (5),TABLE 4 Baseline 11C-PiB PET/CT and CMR Results From Each
Study Participant
Patient #
PiB PET/CT LGE-CMR
Uptake LGE pattern
1 Yes Subendocardial ring LGE
2 Yes Negative
3 Yes Subendocardial ring LGE
4 Yes Subendocardial ring LGE
5 Yes Heterogeneous transmural LGE
6 Yes Heterogeneous transmural LGE
7 Yes Heterogeneous transmural LGE
8 Yes Not done because of azotemia
9 Yes Subendocardial ring LGE
10 Yes Subendocardial ring LGE
11 Yes Not done because of azotemia
12 Yes Subendocardial ring LGE
13 Yes Subendocardial ring LGE
14 No Not done because of azotemia
15 No Negative
16 No Subendocardial ring LGE
17 No Negative
18 No Negative
19 No Negative
20 No Negative
21 No Negative
22 No Negative
CMR was done within 1 month of 11C-PiB PET/CT. The pattern of LGE was classiﬁed
as either negative, subendocardial ring type, or heterogeneous transmural type.
CMR ¼ cardiac magnetic resonance; LGE ¼ late gadolinium enhancement; other
abbreviations as in Table 1.investigators have tried to assess this disease non-
invasively with various imaging techniques. Although
some molecular imaging-based methods have been
successful (8,12), most of them have been unsuc-
cessful for demonstrating amyloid deposits in the
myocardium (13). The CMR has also been successful
in the diagnosis of cardiac amyloidosis (14), but it may
not be speciﬁc for amyloid deposits (15). Therefore,
there is a clinical need to foster imaging-based diag-
nosis into clinical utility.
11C-PiB has been used recently for early detection
and for follow-up of Alzheimer’s dementia (16), a
disease characterized by accumulation of b-amyloid
plaque in the brain parenchyme. It is a radioactive
derivative of benzothiazole that binds with confor-
mational dependence to any type of b-amyloid sheet
structure (7). Indeed, this has been demonstrated in
various mouse models (17) and in human autopsy
studies of the brain (18). The clinical efﬁcacy of the
11C-PiB PET scan to predict the outcome in Alz-
heimer’s dementia patients has recently been high-
lighted (16,19). These ﬁndings led us to investigate
whether 11C-PiB PET/CT may be a simple yet clinically
useful method for detection of cardiac amyloidosis.
Although very preliminary and hypothetical at the
current stage, the ﬁndings of the current study sug-
gest that 11C-PiB PET/CT results might be a useful
surrogate marker of the status of cardiac amyloidosis.
There have been several reports on the diagnosis of
cardiac amyloidosis using simple methods, such as
12-lead electrocardiogram (20) and CMR (9,14,21), but
none of these modalities is speciﬁc for the inﬁltration
of amyloidogenic proteins itself. In this aspect, the
11C-PiB PET/CT provides a unique experience for
detection of the pathophysiological process itself in
cardiac amyloidosis.
The concerns regarding the accuracy of each test
for cardiac amyloidosis are reﬂected by the results of
our cohort as well. Although a small population,
approximately 80% of our patients with endomyo-
cardial biopsy-proven amyloidosis displayed low
voltage on 12-lead electrocardiogram. A previous pa-
per reported a 50% to 60% diagnostic yield with the
low voltage criteria (21). Therefore, although the
suspicion of cardiac amyloidosis can be made with
the low voltage criteria by 12-lead electrocardiogram
(20), its diagnostic yield may not be sensitive enough.
Increased LV wall thickness on echocardiography
with evidence of systemic amyloidosis is assumed to
be diagnostic of cardiac amyloidosis (5). However,
approximately 40% of our patients did not display
increased wall thickness on 2-dimensional echocar-
diography. Moreover, increased wall thickness on
echocardiography is not pathognomonic of cardiac
FIGURE 3 A Patient With False-Negative CMR Result That Was Correctly Diagnosed With 11C-PiB PET/CT
(A) Although the CMR result did not show any late gadolinium enhancement (LGE) in the LV, the endomyocardial biopsy result was positive for
cardiac amyloidosis (Patient #2). (B) The PET/CT showed strong uptake of 11C-PiB in the myocardium. (C) The average wall thickness of the LV
was 12 mm. (D) Low voltage in the limb leads was noted on 12-lead electrocardiogram. Abbreviations as in Figures 1 and 2.
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57amyloidosis, and other potential causes of LV hyper-
trophy must be excluded to diagnose cardiac
amyloidosis on the basis of echocardiography ﬁnd-
ings (5). Even with the combination of both electro-
cardiogram and echocardiography ﬁndings, the
diagnostic accuracy is barely 60% (21).
In line with this, the sensitivity and speciﬁcity of
11C-PiB PET/CT show a potential clinical utility ofTABLE 5 Diagnostic Performance of Each Test in Patients Either
With Biopsy-Proven Cardiac Amyloidosis or Without Evidence of
Cardiac Amyloidosis on Endomyocardial Biopsy
LGE-CMR
Yes No
Biopsy positive
PiB PET/CT uptake Yes 10 1
No 0 1
Biopsy negative
PiB PET/CT uptake Yes 0 0
No 1 6
The diagnostic performance was compared between LGE-CMR and 11C-PiB PET/CT
according to the endomyocardial biopsy results, the gold standard.
Abbreviations as in Tables 1 and 4.PET/CT for diagnosis of cardiac amyloidosis. Even if
taking into account the 2 false-negative 11C-PiB PET/
CT cases, the sensitivity and speciﬁcity of 11C-PiB
PET/CT were at least comparable to CMR for assess-
ment of the amyloid deposits in cardiac amyloidosis,
and these ﬁndings warrant further comparative
studies of the accuracy between each test in a larger
population. In addition, whereas the case of patient 2
demonstrated that 11C-PiB PET/CT may be used
complementarily to aid the diagnosis of cardiac
amyloidosis (Figure 3), there was no case with false-
negative 11C-PiB PET/CT but with positive CMR re-
sults. In support of this, it has been reported in a
previous study that the probability of a false-negative
CMR may be approximately 12% in a biopsy-proven
cardiac amyloidosis (21). Also, the case of Patient #8
demonstrates the unique opportunity of 11C-PiB PET/
CT for the diagnosis of cardiac amyloidosis in the
setting of signiﬁcant azotemia, a situation where
contrast-enhanced CMR cannot be performed (22).
The true importance of our study is that quantita-
tive assessment of amyloid deposit might be possible
by using 11C-PiB PET/CT in cardiac amyloidosis. The
test results indicate that there is potential for the use
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58of 11C-PiB PET/CT in assessing the disease burden, as
shown by the signiﬁcant difference of 11C-PiB uptake
between the chemotherapy naïve group and the pre-
vious chemotherapy group. Attempts to assess amy-
loid burden have also been made with CMR. As shown
by the various LGE ﬁndings on CMR, a global trans-
mural LGE pattern was associated with a more pro-
gressed state of cardiac amyloidosis (i.e., larger LV
mass, worse LV ejection fraction, and worse func-
tional capacity) compared with focal positive LGE
pattern or negative LGE pattern (9). Patients with LGE
were more likely to experience an adverse clinical
event than patients without (21). However, the LGE
pattern in cardiac amyloidosis is diverse even in a
single cut of a given myocardium (9), making the
classiﬁcation obscure in some cases. In addition,
gadolinium cannot be used in patients with azotemia
(22), a ﬁnding that is not infrequently encountered in
systemic amyloidosis, and there have been no data on
whether LGE may reﬂect the amyloid burden after
deﬁnite treatment. Furthermore, it may be virtually
impossible to quantify LGE in a patient with a het-
erogeneous mix of diverse LGE patterns. In contrast,
we were able to quantify the SUV of the myocardium
using the 11C-PiB PET/CT. Especially, considering that
the majority of the patients who had undergone pre-
vious chemotherapy had at least a partial response to
the treatment, the striking difference of 11C-PiB up-
take between the chemotherapy naïve group and the
previous chemotherapy group suggests that the 11C-
PiB PET/CT results may reﬂect active deposition of
amyloid protein in the myocardium. Further in-
vestigations in a larger population and follow-up
scans may give further insight into the mechanism
of the isotope uptake.
STUDY LIMITATIONS. First, the small number of pa-
tients makes some ﬁndings of our study difﬁcult to
generalize. Furthermore, all of our patients had AL
amyloidosis, and whether our ﬁndings extend to other
causes of cardiac amyloidosis, such as senile or he-
reditary amyloidosis, needs further observation. In
this aspect, it is interesting to note that 11C-PiB PET
was valuable for the diagnosis of transthyretin-associated senile amyloidosis in a previous study (8).
Second, we cannot provide data as to whether the
myocardium to blood cavity ratio of 11C-PiB is related
to myocardial blood ﬂow. However, all except 1 pa-
tient were void of any history of coronary artery dis-
ease, and a previous report has also demonstrated that
the retention index of 11C-PiB is unrelated to quanti-
ﬁed myocardial blood ﬂow (8). Third, we did not
perform dynamic PET scans as in a previous study (8).
However, we aimed to develop a relatively simple
method that would be ready for clinical usage, an
objective difﬁcult to achieve with the kinetic model.
Furthermore, the tissue to blood pool ratio tends to
increase after 20 min post-injection (10), and we
assumed that 30min post-injection may be a sufﬁcient
time point to measure the tissue to blood pool ratio.
Last, the current sample number may not be sufﬁcient
to make a reasonable comparison of the diagnostic
performance between 11C-PiB PET/CT and CMR.
CONCLUSIONS
We have shown in this pilot study that 11C-PiB PET/CT
may be valuable for noninvasive diagnosis of cardiac
amyloidosis. Additionally, the signiﬁcant difference
of 11C-PiB uptake between the chemotherapy naïve
patients and the patients who had previous chemo-
therapy warrants further in-depth investigation into
whether 11C-PiB PET/CT can be used as a surrogate for
active light chain deposition in the myocardium. If
conﬁrmed, the ﬁndings here may suggest an objec-
tive, noninvasive tool to assess the degree of cardiac
involvement in systemic amyloidosis, which is valu-
able in deciding the treatment strategy.
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